TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

• TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million.
• VitaCare is a consumer-focused digital healthcare platform.
• TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. 
• TXMD will also enter into a long-term services agreement to continue to utilize the vitaCare platform.
• The transaction is expected to close by Q2 of 2022.
• VitaCare helps patients understand coverage, identify savings opportunities, and facilitate communication between providers and payors. 
• The platform also offers a seamless path for filling a prescription, primarily through its network of third-party pharmacies. 
• GoodRx expects the transaction to contribute under 1% to overall revenue and reduce the adjusted EBITDA margin by approximately 2% in 2022.
• Price Action: TXMD shares are up 38% at $0.29, while GDRX shares are down 6.70% at $14.91 during the market session on the last check Monday.